Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InflaRx (IFRX) Research & Development (2022 - 2025)

Historic Research & Development for InflaRx (IFRX) over the last 4 years, with Q3 2025 value amounting to -$7.3 million.

  • InflaRx's Research & Development rose 4036.56% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year increase of 2378.06%. This contributed to the annual value of -$38.3 million for FY2024, which is 1328.47% up from last year.
  • According to the latest figures from Q3 2025, InflaRx's Research & Development is -$7.3 million, which was up 4036.56% from -$8.2 million recorded in Q2 2025.
  • Over the past 5 years, InflaRx's Research & Development peaked at $11.9 million during Q2 2022, and registered a low of -$15812.4 billion during Q1 2023.
  • Moreover, its 4-year median value for Research & Development was -$8.5 million (2022), whereas its average is -$1560.8 billion.
  • In the last 5 years, InflaRx's Research & Development tumbled by 13453855285.45% in 2023 and then skyrocketed by 9999.99% in 2024.
  • InflaRx's Research & Development (Quarter) stood at -$8.5 million in 2022, then dropped by 2.06% to -$8.7 million in 2023, then rose by 14.99% to -$7.4 million in 2024, then grew by 1.12% to -$7.3 million in 2025.
  • Its Research & Development was -$7.3 million in Q3 2025, compared to -$8.2 million in Q2 2025 and -$7.4 million in Q1 2025.